Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
109Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.96M | $-23.88M | $-2.10 |
| 2024 | $20.22M | $-30.22M | $-3.03 |
| 2023 | $18.69M | $-6.72M | $-0.75 |
| 2022 | $26.50M | $-19.60M | $-3.93 |
| 2021 | $23.76M | $-13.55M | $-3.48 |
Social Signal Score
Earnings
Thu, Nov 19(in 3 months)
Consensus estimate $-0.69 per share
Typical surprise +39.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.77 vs $-0.76miss
- Wed, May 27$-0.23 vs $-0.65beat
- Thu, Mar 5$-0.56 vs $-0.65beat
- Thu, Nov 20$-0.24 vs $-0.81beat
- Thu, Aug 14$-1.23 vs $-0.55miss
- Wed, May 21$-0.07 vs $-0.65beat
Estimates and results for MDWD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
MDWDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (3)
- Newsseekingalpha.com·1d ago·Positive
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·2d ago·Neutral
MediWound Q2 Earnings Call Highlights MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
View source ↗ - Newszacks.com·2d ago·Neutral
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.
View source ↗